Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 6/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496451 | 1.00 | P2RX7 (0.43) | P2RX7PNPTSHRUSP2EDNRA | |
| SCHEMBL6227235 | 0.89 | PNP (0.40) | P2RX7PNPTSHRUSP2EDNRA | |
| SCHEMBL14916463 | 0.88 | HSP90AB1 (0.50) | PNPTSHRUSP2EDNRAHTR2A | |
| SCHEMBL20555316 | 0.87 | YTHDC1 (0.38) | PNPTSHRUSP2EDNRAHTR2A | |
| SCHEMBL20555334 | 0.86 | PNP (0.36) | P2RX7PNPTSHRUSP2EDNRA | |
| SCHEMBL27228495 | 0.86 | YTHDC1 (0.56) | YTHDC1 | |
| SCHEMBL8306098 | 0.85 | P2RX7 (0.43) | P2RX7PNPTSHRUSP2EDNRA | |
| SCHEMBL20555376 | 0.84 | YTHDC1 (0.38) | PNPTSHRUSP2EDNRAHTR2A | |
| SCHEMBL357273 | 0.83 | FDPS (0.45) | P2RX7HDAC6 | |
| SCHEMBL31340868 | 0.83 | FDPS (0.45) | P2RX7HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157739-B2 | Hypoxanthine compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-12-03 | — | — | US | disclosed |
| WO-2024233848-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12110292-B2 | Ligands to cereblon (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| CN-112638380-B | Cerebellar protein (CRBN) ligands | 达纳-法伯癌症研究所有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| US-11530219-B2 | Ligands to cereblon (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| EP-1597258-B1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD THEREOF, APPLICATION OF SAME AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070185140-A1 | Novel purine derivatives, method for preparing them, their application as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S. A. (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
| EP-1597258-A2 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD THEREOF, APPLICATION OF SAME AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073595-A2 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD THEREOF, APPLICATION OF SAME AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA S.A. (FR) | 2004-09-02 | — | — | WO | disclosed |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1349857-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055521-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | P2RX7 32/4885PNP 284/4885TSHR 243/4885 |
| US-12157739-B2 | Hypoxanthine compounds | HPRT1, APRT, IMPDH1 | P2RX7 932/4885PNP 51/4885TSHR 4650/4885 |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | P2RX7 2152/4885PNP 837/4885TSHR 1613/4885 |
| US-12110292-B2 | Ligands to cereblon (CRBN) | CRBN, CRKL, CDR2 | P2RX7 1850/4885PNP 3880/4885TSHR 3242/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | P2RX7 1887/4885PNP 823/4885TSHR 4519/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | P2RX7 2001/4885PNP 827/4885TSHR 4516/4885 |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | CRBN, CRKL, CDR2 | P2RX7 1850/4885PNP 3880/4885TSHR 3242/4885 |
| US-11530219-B2 | Ligands to cereblon (CRBN) | CRBN, CRKL, CDR2 | P2RX7 1850/4885PNP 3880/4885TSHR 3242/4885 |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | OPRL1, CNR1, CNR2 | P2RX7 76/4885PNP 193/4885TSHR 275/4885 |
| US-20070185140-A1 | Novel purine derivatives, method for preparing them, their application as medicinal products, pharmaceutical compositions and novel use | NR4A3, NR4A1, ADORA3 | P2RX7 100/4885PNP 341/4885TSHR 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.